Axcan Is Buying European Specialty Pharma Eurand For $583Mx
This article was originally published in The Pink Sheet Daily
Executive Summary
At a 9% premium to Eurand's closing stock price Nov. 30, the value is disappointing, but majority investor Warburg Pincus favors the deal and competitive bids are unlikely.
You may also be interested in...
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Current European-based specialty pharma companies are in transition, awaiting key regulatory decisions, overhauling management or engaged in M&A. Their fates will help answer a critical question: under what circumstances can this class of companies continue to deliver long term growth as independent entities?
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Current European-based specialty pharma companies are in transition, awaiting key regulatory decisions, overhauling management or engaged in M&A. Their fates will help answer a critical question: under what circumstances can this class of companies continue to deliver long term growth as independent entities?
European Cell Therapy Players TiGenix And Cellerix Join Forces For Critical Mass, Cash
Lacking critical mass individually, Belgium's TiGenix and Spain's Cellerix have joined forces, attracting €33 million in new investment.